fr   en
Acquisitions
Select a company :
Choose date:
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10      »      
Date Acquiring pharma company Acquired biotech company Amount Terms / other
2010-09-09 Cellectis (France) Cyto Pulse Sciences (USA) $2.2 million paid in cash
See details
2010-08-30 Lonza (Switzerland) Vivante GMP Solutions (USA)   See details
2010-08-23 Roche (Switzerland) BioImagene (USA) $100 million See details
2010-07-28 FGK Clinical Research (Germany) BlankaMedika (Hungary) Undisclosed amount See details
2010-07-20 Actelion (Switzerland) Trophos (France) €125 to 195 million depending on market approval of olesoxime by the FDA and overall pipeline progression. See details
2010-07-14 Evotec (Germany) Develogen (Germany) up to € 14m in shares and an earn-out component in cash.
The € 14m in shares will be created using Evotec’s authorised capital with an attributed value per share of € 2.00. € 8m (4m shares) are issued to the sellers at closing; € 6m (3m shares) are conditional.
See details
2010-06-30 Sanofi-Aventis (France) TargeGen (USA) Under the terms of the agreement, Sanofi-Aventis will make an upfront payment of $ 75 million upon closing of the transaction. Further milestones payments will occur at different stages of development of TargeGen lead product TG 101348.
The total amount of all payments, including the upfront payment, could reach $ 560 million.
See details
2010-06-07 Grifols (Spain) Talecris Biotherapeutics (USA) $3.4 billion (€2.8 billion). See details
2010-06-01 Pharma Omnium International (France) CellVir (France) undisclosed See details
2010-06-01 Centocor Ortho Biotech (USA) RespiVert (UK) Financial terms were not disclosed. See details
2010-05-20 Lonza (Switzerland) MODA Technology Partners (USA) undisclosed See details
2010-04-26 ALK-Abelló (Denmark) Fornix' Allergy Division, Artu Biologicals (The Netherlands) € 19.6 million See details
2010-04-26 ExonHit Therapeutics (France) RedPath Integrated Pathology (USA) $ 12.5 million in cash and $ 10 million in stock.
Starting in 2012, RedPath’s current shareholders may receive subsequent additional payments of up to $9.5 million dependent on the achievement of specific sales targets.
See details
2010-03-01 Baxter (USA) ApaTech (UK) up to $330 million (€243.6 million)
The agreement includes an upfront cash payment of $240 million.
Baxter may make additional payments of up to $90 million related to the achievement of sales milestones.
See details
2010-02-28 Merck KGaA (Germany) Millipore (USA) $ 7.3 billion (€ 5.3 billion) See details
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10      »